Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts.
Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts.
复制标题
DOI:
10.1158/2159-8290.cd-17-0935
复制
发表时间:
2018-05
期刊:
影响因子:
28.2
通讯作者:
Farago AF
中科院分区:
文献类型:
--
作者:
Drapkin BJ;George J;Christensen CL;Mino-Kenudson M;Dries R;Sundaresan T;Phat S;Myers DT;Zhong J;Igo P;Hazar-Rethinam MH;Licausi JA;Gomez-Caraballo M;Kem M;Jani KN;Azimi R;Abedpour N;Menon R;Lakis S;Heist RS;Büttner R;Haas S;Sequist LV;Shaw AT;Wong KK;Hata AN;Toner M;Maheswaran S;Haber DA;Peifer M;Dyson N;Thomas RK;Farago AF
Small cell lung cancer (SCLC) patient-derived xenografts (PDX) can be generated from biopsies or circulating tumor cells (CTC), though scarcity of tissue and low efficiency of tumor growth have previously limited these approaches. Applying an established clinical-translational pipeline for tissue collection and an automated microfluidic platform for CTC enrichment, we generated 17 biopsy-derived PDXs and 17 CTC-derived PDXs in a 2-year timeframe, at 89% and 38% efficiency, respectively. Whole-exome sequencing showed that somatic alterations are stably maintained between patient tumors and PDXs. Early-passage PDXs maintain the genomic and transcriptional profiles of the founder PDX. In vivo treatment with etoposide and platinum (EP) in 30 PDX models demonstrated greater sensitivity in PDXs from EP-naïve patients, and resistance to EP corresponded to increased expression of a MYC gene signature. Finally, serial CTC-derived PDXs generated from an individual patient at multiple time points accurately recapitulated the evolving drug sensitivities of that patient’s disease. Collectively, this work highlights the translational potential of this strategy.